Last reviewed · How we verify

CCRT+GP — Competitive Intelligence Brief

CCRT+GP (CCRT+GP) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination chemotherapy and radiotherapy regimen. Area: Oncology.

phase 3 Combination chemotherapy and radiotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CCRT+GP (CCRT+GP) — Sun Yat-sen University. CCRT+GP combines concurrent chemoradiotherapy with gemcitabine and cisplatin followed by adjuvant chemotherapy to treat locally advanced cancers through combined cytotoxic and radiation effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
CCRT+GP TARGET CCRT+GP Sun Yat-sen University phase 3 Combination chemotherapy and radiotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination chemotherapy and radiotherapy regimen class)

  1. Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CCRT+GP — Competitive Intelligence Brief. https://druglandscape.com/ci/ccrt-gp. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: